If you want a simple translation of "journalistic breakthrough", this is it: Prof. Ashok Shetty's team at Texas A&M's Institute for Regenerative Medicine has developed a liquid nasal spray that, according to research, reverses aging in the brain. Just two doses restored old mice to the brain function of young mice. The article was published in the Journal of Extracellular Vesicles in April 2026.
What is actually in the spray?
The active ingredient is something called extracellular vesicles, tiny particles that cells secrete that contain signaling molecules. The team "charged" them with specific microRNAs that know how to suppress inflammation and restore mitochondrial function.
When the spray is sprayed into the nose, the vesicles climb the olfactory nerve and reach the brain tissue directly. They bypass the blood-brain barrier, which is a huge obstacle for most drugs.
What happens after the dish?
The team followed old mice that received the spray, and compared them with mice that received a placebo. The differences were dramatic:
- Reduction of chronic inflammation: the levels of inflammatory cytokines in the brain (IL-6, TNF-α, IL-1β) decreased dramatically
- Mitochondrial function restoration: ATP production returned to a youthful level, free radical production decreased
- Improvement in memory: in object recognition tests and maze tests, the mice showed a significant improvement
- Long-term effect: the benefits lasted for months, even beyond the treatment cycle
"We give neurons their spark back by reducing oxidative stress and reactivating the mitochondria," Shetty explained.
How does it work biologically?
The aging brain suffers from what is called chronic neuroinflammation: inflammation at the basic level that is not visible from the outside but damages the function of the neurons. The two main inflammatory pathways that the spray suppressed are:
- NLRP3 inflammasome: a protein complex that activates a powerful inflammatory response. It is increased in Alzheimer's and Parkinson 's brains
- cGAS-STING pathway: a pathway activated by damaged DNA, which increases with age
In addition to suppressing inflammation, the microRNAs in the spray "reboot" the mitochondria in neurons, allowing them to return to normal energy production.
What next?
This is still a preclinical study in mice. But the team is optimistic for three reasons:
- The route of transmission is known: intranasal sprays are already used in the clinic (migraine drugs, naloxone). There is no need to confirm a new route
- The composition is solid: Extracellular vesicles have been studied for years. They are not a new regulatory problem
- Obvious effect: only 2 doses with a long-term effect means high sensitivity
The phase of clinical trials in humans is expected to begin in about a year. If the trials are successful, within 5-7 years it may be an available treatment.
What does this mean about you?
As of today, there is nothing to do. But the research offers an approach: chronic encephalitis is a real problem, and it has solutions. Dietary changes (less sugar, more omega-3), exercise, quality sleep, and less stress, all of these reduce the inflammatory burden in the brain even without a spray.
💬 תגובות (0)
היו הראשונים להגיב על המאמר.